$INFU released their 2013 Q2 earnings and completed their conference call. You can read the 10Q and conference call transcripts from the links. Since the recent failed take private situation, I wanted to review what is happening with the company. Positive Revenue up 4% from Q2 2012 Management has made strides in expanding their business model outside of the oncology market. Meaningful revenue was not shown this quarter, but it’s good to see that the company is expanding to other markets. Long-term care is one of markets, which is a good market to enter, along with post-surgical pain. These...
Update on $INFU and Ryan Morris
Due to travel and my day job, I have not had a lot of time to keep up with the blog. Over the past weeks, I have been keeping track of my investments and potential ideas, but just haven’t had enough time to put something on the blog. It could also have to do with the stock market’s continual rise and not finding too many interesting ideas. I’ve written up InfuSystems ($INFU) awhile back and with the release of their latest quarterly earnings, some new developments have happened that create an interesting situation. First, the results for the first...